PL418202A1 - Sposób indukowania ex vivo limfocytów o fenotypie CD8+CD25+FOXP3-, limfocyty indukowane tym sposobem do zastosowanie w sposobach zapobiegania i leczenia chorób oraz roztwór białek z pasożyta z grupy helmintów do zastosowania w sposobie indukowania limfocytów o fenotypie CD8+CD25+FOXP3-u potrzebującego tego osobnika - Google Patents
Sposób indukowania ex vivo limfocytów o fenotypie CD8+CD25+FOXP3-, limfocyty indukowane tym sposobem do zastosowanie w sposobach zapobiegania i leczenia chorób oraz roztwór białek z pasożyta z grupy helmintów do zastosowania w sposobie indukowania limfocytów o fenotypie CD8+CD25+FOXP3-u potrzebującego tego osobnikaInfo
- Publication number
- PL418202A1 PL418202A1 PL418202A PL41820216A PL418202A1 PL 418202 A1 PL418202 A1 PL 418202A1 PL 418202 A PL418202 A PL 418202A PL 41820216 A PL41820216 A PL 41820216A PL 418202 A1 PL418202 A1 PL 418202A1
- Authority
- PL
- Poland
- Prior art keywords
- lymphocytes
- phenotype
- solution
- foxp3
- inducing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 210000004698 lymphocyte Anatomy 0.000 title abstract 7
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 title abstract 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 title abstract 5
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 title abstract 5
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 244000045947 parasite Species 0.000 title abstract 2
- 244000000013 helminth Species 0.000 title 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 230000000392 somatic effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/405—Invertebrates antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Przedmiotem zgłoszenia jest sposób indukowania ex vivo limfocytów o fenotypie CD8+CD25+, w którym izolowane komórki krwi osobnika, kontaktuje się ex vivo z roztworem białek somatycznych i/lub wydalniczo - wydzielniczych z pasożyta z grupy helmintów i/lub z funkcyjnymi frakcjami białkowymi z wymienionego roztworu i/lub z rekombinowanymi białkami o sekwencji aminokwasowej identycznej w przynajmniej 70% z białkami wymienionego roztworu zachowującymi aktywność białek wymienionego roztworu, przy czym uzyskane indukowane limfocyty o fenotypie CD8+CD25+ nie wykazują ekspresji czynnika transkrypcyjnego FOXP3. Zgłoszenie dotyczy też limfocytów uzyskanych wymienionym sposobem do zastosowania w sposobach zapobiegania i leczenia chorób związanych z obecnością autoreaktywnych limfocytów T, w szczególności chorób autoimmunizacyjnych, a także roztworu białek somatycznych i wydalniczo - wydzielniczych z pasożyta z grupy helmintów i/lub funkcyjnych frakcji białkowych z wymienionego roztworu i/lub rekombinowanych białek do zastosowania w sposobie indukowania limfocytów o fenotypie CD8+CD25+FOXP3- u potrzebującego tego osobnika.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL418202A PL418202A1 (pl) | 2016-08-04 | 2016-08-04 | Sposób indukowania ex vivo limfocytów o fenotypie CD8+CD25+FOXP3-, limfocyty indukowane tym sposobem do zastosowanie w sposobach zapobiegania i leczenia chorób oraz roztwór białek z pasożyta z grupy helmintów do zastosowania w sposobie indukowania limfocytów o fenotypie CD8+CD25+FOXP3-u potrzebującego tego osobnika |
| FIEP17772758.3T FI3493835T3 (fi) | 2016-08-04 | 2017-08-04 | Menetelmä suppressorilymfosyyttien ex vivo -induktioon käyttämällä loismadoista peräisin olevaa proteiiniliuosta |
| EP17772758.3A EP3493835B1 (en) | 2016-08-04 | 2017-08-04 | Method for ex vivo induction of suppressor lymphocytes using a solution of proteins from helminth parasites |
| PCT/IB2017/054790 WO2018025236A1 (en) | 2016-08-04 | 2017-08-04 | Method for ex vivo induction of suppressor lymphocytes using a solution of proteins from helminth parasites, lymphocytes produced by this method and uses thereof |
| PL17772758.3T PL3493835T3 (pl) | 2016-08-04 | 2017-08-04 | Sposób indukowania ex vivo limfocytów supresorowych roztworem białek z pasożyta z grupy helmintów |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL418202A PL418202A1 (pl) | 2016-08-04 | 2016-08-04 | Sposób indukowania ex vivo limfocytów o fenotypie CD8+CD25+FOXP3-, limfocyty indukowane tym sposobem do zastosowanie w sposobach zapobiegania i leczenia chorób oraz roztwór białek z pasożyta z grupy helmintów do zastosowania w sposobie indukowania limfocytów o fenotypie CD8+CD25+FOXP3-u potrzebującego tego osobnika |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL418202A1 true PL418202A1 (pl) | 2018-02-12 |
Family
ID=59969189
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL418202A PL418202A1 (pl) | 2016-08-04 | 2016-08-04 | Sposób indukowania ex vivo limfocytów o fenotypie CD8+CD25+FOXP3-, limfocyty indukowane tym sposobem do zastosowanie w sposobach zapobiegania i leczenia chorób oraz roztwór białek z pasożyta z grupy helmintów do zastosowania w sposobie indukowania limfocytów o fenotypie CD8+CD25+FOXP3-u potrzebującego tego osobnika |
| PL17772758.3T PL3493835T3 (pl) | 2016-08-04 | 2017-08-04 | Sposób indukowania ex vivo limfocytów supresorowych roztworem białek z pasożyta z grupy helmintów |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17772758.3T PL3493835T3 (pl) | 2016-08-04 | 2017-08-04 | Sposób indukowania ex vivo limfocytów supresorowych roztworem białek z pasożyta z grupy helmintów |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3493835B1 (pl) |
| FI (1) | FI3493835T3 (pl) |
| PL (2) | PL418202A1 (pl) |
| WO (1) | WO2018025236A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773640A1 (en) * | 2018-04-05 | 2021-02-17 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Larval preparation of heligmosomoides polygyrus bakeri as well as methods of making it and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050118655A1 (en) * | 2003-11-17 | 2005-06-02 | University Of Iowa Research Foundation | Use of parasitic biological agents for diseases prevention and control |
| WO2013039872A1 (en) * | 2011-09-12 | 2013-03-21 | Tufts Medical Center | Compositions and methods for treating inflammatory bowel diseases |
| WO2013192215A1 (en) * | 2012-06-18 | 2013-12-27 | Yale University | Compositions and methods for diminishing an immune response |
-
2016
- 2016-08-04 PL PL418202A patent/PL418202A1/pl unknown
-
2017
- 2017-08-04 WO PCT/IB2017/054790 patent/WO2018025236A1/en not_active Ceased
- 2017-08-04 PL PL17772758.3T patent/PL3493835T3/pl unknown
- 2017-08-04 FI FIEP17772758.3T patent/FI3493835T3/fi active
- 2017-08-04 EP EP17772758.3A patent/EP3493835B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018025236A1 (en) | 2018-02-08 |
| FI3493835T3 (fi) | 2023-09-20 |
| EP3493835B1 (en) | 2023-08-16 |
| PL3493835T3 (pl) | 2024-02-12 |
| EP3493835A1 (en) | 2019-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bushey et al. | Characteristics and safety assessment of intractable proteins in genetically modified crops | |
| BR112013026114A2 (pt) | composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas | |
| GB2562406A (en) | A method of non destructive monitoring of biological processes in microfluidic tissue culture systems | |
| EP3995142A3 (en) | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof | |
| AR102538A1 (es) | Métodos de selección de la línea celular t y donante de la misma para la terapia adoptiva celular | |
| MX2019003148A (es) | Base de datos, de datos moleculares, omicos, de inmunoterapia, metabolicos, epigeneticos y clinicos, integrados. | |
| MX2018000293A (es) | Analisis genealogico y genetico para identificacion de informacion de apellidos y lugar de nacimiento. | |
| BR112018067536A2 (pt) | sistema de transpóson e métodos de uso | |
| EA201790789A1 (ru) | Композиции и способы, предназначенные для ингибирования экспрессии гена hao1 (оксидазы 1 гидроксикислот (гликолат-оксидазы)) | |
| BR112013018744A2 (pt) | método para produzir um polipetídeo ou uma proteína recombinante | |
| MX2017008567A (es) | Dnasa modificada y usos de la misma. | |
| MX2018011162A (es) | Metodos de purificacion de colageno 7. | |
| AR072136A1 (es) | Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21 | |
| MX2022006689A (es) | Métodos de tratamiento usando proteínas de unión al transcrito 7 similar a inmunoglobulina (ilt7). | |
| WO2015150492A3 (en) | An isolated donor mhc-derived peptide and uses thereof | |
| AR109279A1 (es) | Anticuerpos anti plazomicina y métodos de uso de los mismos | |
| EA201690826A1 (ru) | Рекомбинантные гликопротеиды и их применения | |
| BR112014023496A2 (pt) | mutantes c-raf que conferem resistência a inibidores de raf | |
| Zheng et al. | Biological effects of bone marrow mesenchymal stem cells on hepatitis B virus in vitro | |
| BR112015024516A2 (pt) | métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação | |
| MX2019010829A (es) | Metodos y composiciones para suministrar agentes activos de acido micofenolico a mamiferos no humanos. | |
| MX378232B (es) | Promotor recombinante con aumento de la expresión específica de fibra. | |
| EA202090990A1 (ru) | Системы и способы получения в-клеток генетически модифицированных для экспрессии выбранных антител | |
| Mateo Morejón et al. | Allergenic activity of the native Blo t 2 purified from Blomia tropicalis culture | |
| Guéorguiev et al. | Two new species of Anatrichis LeConte (Coleoptera: Carabidae: Oodini) from Japan, with notes on the taxonomic position of Oodes infimus Andrewes |